Preclinical Retinal Disease Models: Applications in Drug Development and Translational Research

Area of Science:

• Ophthalmology and Translational Medicine
• Preclinical Drug Development Models

Background:

• The retina is an ideal organ for advanced therapy research due to immune privilege, vascular/neuronal networks, accessibility, and imaging capabilities.
• Preclinical retinal models provide insights into inflammation, angiogenesis, fibrosis, and hypoxia.

Purpose of the Study:

• To review the role of retinal models in translational drug development.
• To highlight the utility of the retina for studying advanced therapies.
• To emphasize the integration of 3Rs principles and novel imaging.

Main Methods:

• Review of preclinical retinal disease models.
• Utilizing clinically translatable bioimaging tools (fundoscopy, OCT, CSLO, FA, OKT, ERG).
• Focus on innovations in anti-inflammatory, anti-angiogenic, and neuroprotective strategies.

Main Results:

• Retinal models offer insights into ocular and systemic diseases like rheumatoid arthritis, Alzheimer's, and fibrosis.
• Clinically translatable imaging tools enhance understanding of disease mechanisms.
• These models drive therapeutic innovations and have broader systemic implications.

Conclusions:

• Retinal models are pivotal for advancing drug development for ocular and systemic conditions.
• Integration of 3Rs principles and advanced imaging enhances therapeutic precision and ethical research.
• Retinal research paves the way for more predictive and human-relevant drug development approaches.